VivoSeq
Other

IC-MPGN

1

Pipeline Programs↗

1

Active Trials↗

4

Companies Involved↗

IC-MPGN is an early-stage landscape with 1 program across 4 companies. The most active players are Novartis, Eli Lilly, AstraZeneca. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

1 program

Phase 3Eli Lilly logo

Eli Lilly

1 program

Phase 3AstraZeneca logo

AstraZeneca

0 programs

PreclinicalApellis Pharmaceuticals logo

Apellis Pharmaceuticals

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 31

Iptacopan

Novartis

Approved
No programs

Analysis

Trial Status

3

clinical trials

Completed1 · 33%
Approved for marketing1 · 33%
Recruiting1 · 33%

Clinical Trials

Trial Activity

A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN
Completed·AstraZeneca logoAstraZeneca·Phase 2·NCT03124368·6 enrolled
C3G/Primary IC-MPGN EAP
Approved for marketing·Apellis Pharmaceuticals logoApellis Pharmaceuticals·N/A·NCT04729062
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Iptacopan (LNP023) in Idiopathic Immune-complex-mediated Membranoproliferative Glomerulonephritis (IC-MPGN)
Recruiting·Novartis logoNovartis·Phase 3·NCT05755386·106 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)